Insights into CD47/SIRPα axis-targeting tumor immunotherapy [0.03%]
靶向肿瘤免疫治疗中CD47/SIRPα轴的作用机制及应对策略新进展
Xuyao Zhang,Jiajun Fan,Dianwen Ju
Xuyao Zhang
During the last decade, inhibitors targeting immune checkpoint programmed death ligand 1/PD-1 and cytotoxic T-lymphocyte-associated protein 4 have been one of the most significant advances for cancer therapy in clinic. However, most of thes...
Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities [0.03%]
Ado-曲妥珠单抗_emtansine引起的毒性的机制：对ADC相关毒性更好理解的途径
Yukinori Endo,Nishant Mohan,Milos Dokmanovic et al.
Yukinori Endo et al.
In order to improve the safety of novel therapeutic drugs, better understanding of the mechanisms of action is important. Ado-trastuzumab emtansine (also known as T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2...
A blocking antibody against canine CSF-1R maturated by limited CDR mutagenesis [0.03%]
有限的CDR诱变成熟的犬CSF-1R阻断抗体
Breno C B Beirão,Teresa P Raposo,Louise M Imamura et al.
Breno C B Beirão et al.
CSF-1R is a receptor mostly associated with the mononuclear phagocytic system. However, its expression within tumors has been linked with poor prognosis in both humans and dogs. Accordingly, several reports have demonstrated the beneficial ...
Models to inform neutralizing antibody therapy strategies during pandemics: the case of SARS-CoV-2 [0.03%]
用于大流行期间中和抗体治疗策略的预测模型——以SARS-CoV-2为例
Donovan Guttieres,Anthony J Sinskey,Stacy L Springs
Donovan Guttieres
Background: Neutralizing antibodies (nAbs) against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) can play an important role in reducing impacts of the COVID-19 pandemic, complementing ongoing public health ...
Bo Wang,Sachith Gallolu Kankanamalage,Jianbo Dong et al.
Bo Wang et al.
In this review, we have summarized the current landscape of therapeutic antibody optimization for successful development. By engineering antibodies with display technology, computer-aided design and site mutagenesis, various properties of t...
High-specificity antibodies and detection methods for quantifying phosphorylated tau from clinical samples [0.03%]
高特异性抗体及临床样本总tau和磷酸化tau检测方法学的建立与应用
Monika Arbaciauskaite,Yu Lei,Yong Ku Cho
Monika Arbaciauskaite
The ability to measure total and phosphorylated tau levels in clinical samples is transforming the detection of Alzheimer's disease (AD) and other neurodegenerative diseases. In particular, recent reports indicate that accurate detection of...
Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer [0.03%]
白细胞免疫球蛋白样受体B亚家族：癌症治疗靶标
Mi Deng,Heyu Chen,Xiaoye Liu et al.
Mi Deng et al.
Inhibitory leukocyte immunoglobulin-like receptors (LILRBs 1-5) transduce signals via intracellular immunoreceptor tyrosine-based inhibitory motifs that recruit phosphatases to negatively regulate immune activation. The activation of LILRB ...
Li Feng,Lin Chen,Amanda Murphy et al.
Li Feng et al.
There is emerging, intense interest in antibody combination therapies. However, antibody combination therapies pose unique intellectual property challenges. In some instances, it may be difficult to obtain patents with claims that provide i...
Mahendra P Deonarain,Quinn Xue
Mahendra P Deonarain
The pharmacokinetic-pharmacodynamic relationship is extremely complex and tumour drug penetration is one key parameter influencing therapeutic efficacy. In the context of antibody-drug conjugates (ADCs), which has undergone many innovation ...
A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy [0.03%]
一种新颖的TIM-3抗体通过受体内吞作用产生癌症免疫治疗效果
Zhihui Kuang,Li Li,Pan Zhang et al.
Zhihui Kuang et al.
Background: Strategies to reinvigorate exhausted T cells have achieved great efficacy in certain subpopulations of tumor patients. Blocking the antibodies that target programmed cell death protein 1 (PD-1) and cytotoxic T...